Last reviewed · How we verify
Safety and Efficacy of AbobotulinumtoxinA for the Treatment of Glabellar Lines
An interventional phase 2 study to evaluate safety and efficacy of AbobotulinumtoxinA treatment for glabellar lines
Details
| Lead sponsor | Galderma R&D |
|---|---|
| Phase | PHASE2 |
| Status | COMPLETED |
| Enrolment | 401 |
| Start date | Mon Nov 26 2018 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Thu Aug 20 2020 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Glabellar Frown Lines
Interventions
- AbobotulinumtoxinA dose level 1 or 2
- placebo
- AbobotulinumtoxinA dose 3
- AbobotulinumtoxinA dose 4
Countries
United States